Observational studyClinical research in cardiology : official journal of the German Cardiac Society2018
Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents.
Observational study in Clinical research in cardiology : official journal of the German Cardiac Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy of Drug-Coated Balloon Approaches forFrontiers in cardiovascular medicine · 2022Pooled it
- Pooled it
- Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Trial
- Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Trial
- Cardiovascular stent technologies for coronary and valvular heart disease: the potential of 3D printing for stent fabrication.Nature reviews. Cardiology · 2026Review
- Determinants of In-Stent Restenosis in ST-Elevation Myocardial Infarction: Insights from a Single-Center Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Observational
- In-Stent Restenosis Pathophysiology and Risk Factors: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Stent thrombosis: a contemporary guide to definitions, risk factors, and management.Frontiers in cardiovascular medicine · 2025Review
- Routinely Available Inflammatory Biomarkers Are Not Associated With Target Lesion Revascularization After Coronary Intervention.JACC. Advances · 2025Article
- De-escalation of antithrombotic treatment after acute coronary syndrome, a new paradigm.Internal and emergency medicine · 2024Review
- Technological Advances Are Associated With Better Clinical Outcomes of Percutaneous Coronary Intervention in Patients With Unprotected Left Main Disease.Journal of the American Heart Association · 2024Article
- Percutaneous Coronary Intervention of Left Main Disease: Outcome After 1-year Follow-up at a Tertiary Hospital in Vietnam.Interventional cardiology (London, England) · 2024Article
- Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery.Journal of the American Heart Association · 2022Article
- Balloon expandable coronary stent materials: a systematic review focused on clinical success.In vitro models · 2022Review
- Serial changes in the quantitative flow ratio in patients with intermediate residual stenosis after percutaneous coronary intervention.Heart and vessels · 2022Article
- Article
- Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Article
- Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?Journal of clinical medicine · 2019Review
- Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOld-generation drug-eluting coronary stents (o-DES) have despite being safe and effective been associated with an increased propensity of late stent thrombosis (ST). We evaluated ST rates in o-DES, new-generation DES (n-DES) and bare metal stents (BMS) the first year (< 1 year) and beyond 1 year (> 1 year).
methodsWe evaluated all implantations with BMS, o-DES (Cordis Cypher, Boston Scientific Taxus Liberté and Medtronic Endeavor) and n-DES in the Swedish coronary angiography and angioplasty registry (SCAAR) between 1 January 2007 and 8 January 2014 (n = 207 291). All cases of ST (n = 2 268) until 31 December 2014 were analyzed.
resultsThe overall risk of ST was lower in both n-DES and o-DES compared with BMS up to 1 year (n-DES versus BMS: adjusted risk ratio (RR) 0.48 (0.41-0.58) and o-DES versus BMS: 0.56 (0.46-0.67), both p < 0.001). From 1 year after stent implantation and onward, the risk for ST was higher in o-DES compared with BMS [adjusted RR, 1.82 (1.47-2.25], p < 0.001). N-DES were associated with similar low ST rates as BMS from 1 year and onward [adjusted RR 1.21 (0.94-1.56), p = 0.135].
conclusionNew-generation DES were associated with lower ST rates in comparison to BMS during the first-year post-stenting. After 1 year, n-DES and BMS were associated with similar ST rates.
trial registrationThis study was a retrospective observational study and as such did not require clinical trial database registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.